Beranda › Leukemia Limfositik Kronis › North Carolina › Durham
Uji klinis Leukemia Limfositik Kronis di Durham, NC
27 studi untuk Leukemia Limfositik Kronis mencari peserta di lokasi sekitar Durham (dalam radius sekitar 30 mil). Buka studi untuk melihat kriteria peserta dan cara menghubungi tim studi.
Teks studi resmi (Bahasa Inggris)
Merekrut peserta untuk studi di sini? Tampilkan di bagian atas halaman ini — $99 selama 30 hari →
Testing the Addition of Anti-Cancer Drug Sonrotoclax, to the Standard Treatment Zanubrutinib, for Previously Untreated CLL/SLL
Menerima pesertaFase 3
- Duke University Medical Center, Durham
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Menerima pesertaStudi observasionalSukarelawan sehat diterima
- Durham VA Medical Center, Durham
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study
Menerima pesertaFase 3
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
- University of North Carolina-Hillsborough Campus, Hillsborough · 13 mi jauhnya
A Study to Investigate Progression-Free Survival With Sonrotoclax Plus Obinutuzumab Or Sonrotoclax Plus Rituximab Compared With Venetoclax Plus Rituximab Treatment In Patients With Relapsed and/or Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CELESTIAL-RRCLL)
Menerima pesertaFase 3
- University of North Carolina At Chapel Hill, Chapel Hill · 10 mi jauhnya
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
Menerima pesertaFase 3
- Duke University Medical Center, Durham
A Study to Evaluate the Safety and Efficacy of Tacabrutideg (BGB-16673) Compared to Pirtobrutinib in Adults With Relapsed/Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Menerima pesertaFase 3
- Duke University Medical Center, Durham
- University of North Carolina At Chapel Hill, Chapel Hill · 10 mi jauhnya
Single-arm Study of IgPro20 in Adults With Secondary Immune Deficiencies Due to Hematologic Malignancies Treated With B-cell Targeting Chimeric Antigen Receptor T-cell and T-cell Redirecting Therapies
Menerima pesertaFase 3
- Duke University, Durham
A Study of NX-5948 in Adults With CLL/SLL Previously Treated With a Bruton's Tyrosine Kinase Inhibitor and a B-cell Lymphoma-2 Inhibitor (DAYBreak CLL-201)
Menerima pesertaFase 2
- Duke University, Durham
Testing the Effectiveness of the Anti-cancer Drug, Mirdametinib, in Treating Relapsed, Refractory Chronic Lymphocytic Leukemia
Menerima pesertaFase 2
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill · 10 mi jauhnya
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
Menerima pesertaFase 1/2
- UNC School of Medicine, Division of Hematology, Chapel Hill · 10 mi jauhnya
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
Menerima pesertaFase 1/2
- University of North Carolina at Chapel Hill/ University of North Carolina Medical Center, Chapel Hill · 10 mi jauhnya
Phase 2 Study of Disease Risk Mutation-Guided Finite Acalabrutinib+Venetoclax for Relapsed CLL Post-1L Finite cBTKi+BCL2i ± Obinutuzumab
Menerima pesertaFase 2
- Research Site, Durham
A Study of Lonitoclax (ZE50-0134) in Relapsed or Refractory B-cell Malignancies
Menerima pesertaFase 1
- University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies
Menerima pesertaFase 1
- Duke University Medical Center, Durham
Combating Cancer-Related Fatigue: A Personalized Supportive Care Program
Menerima peserta
- North Carolina Basnight Cancer Hospital, Chapel Hill · 10 mi jauhnya
Registry of Older Patients With Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma
Menerima pesertaFase 4
- Duke University Medical Center, Durham
A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib
Menerima pesertaFase 4
- Duke University Medical Center, Durham
Study of SGR-1505 in Mature B-Cell Neoplasms
Menerima pesertaFase 1
- Duke University, Durham
Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL)
Menerima pesertaFase 2
- University of North Carolina /ID# 233313, Chapel Hill · 10 mi jauhnya
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Menerima pesertaFase 2
- The University of North Carolina at Chapel Hill, Chapel Hill · 10 mi jauhnya
AS-1763 in Patients With Previously Treated CLL/SLL or Non-Hodgkin Lymphoma
Menerima pesertaFase 1
- Duke University, Durham
Tissue, Blood, and Body Fluid Sample Collection From Patients With Hematologic Cancer
Menerima pesertaStudi observasional
- Lineberger Comprehensive Cancer Center at University of North Carolina - Chapel Hill, Chapel Hill · 10 mi jauhnya
A Randomized Phase II Study Of Bruton Tyrosine Kinase Inhibitor With Or Without Venetoclax In Veterans With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
Menerima pesertaFase 2
- Durham VA Medical Center, Durham, NC, Durham
A Study of AC676 for the Treatment of Relapsed/Refractory B-Cell Malignancies
Menerima pesertaFase 1
- University of North Carolina, Chapel Hill · 10 mi jauhnya
CAP-100 for Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia
Menerima pesertaFase 1
- Duke University, Durham
Uji klinis Leukemia Limfositik Kronis di kota lain
- Boston, MA31 studi
- Columbus, OH28 studi
- Washington, DC22 studi
- Seattle, WA20 studi
- Rochester, MN19 studi
- New York City, NY18 studi
- Houston, TX17 studi
- Baldwin Park, CA16 studi
- Milwaukee, WI15 studi
- Chicago, IL14 studi
- Cincinnati, OH14 studi
- Nashville, TN13 studi
Studi lain di Durham
- Kanker Payudara63 studi
- Kanker (semua jenis)58 studi
- Kanker Paru Non-Sel Kecil39 studi
- Mieloma Multipel37 studi
- Kanker Metastatik33 studi
- Leukemia Mieloid Akut33 studi
- Kanker Paru32 studi
- Kanker Prostat32 studi
- Kanker Kolorektal28 studi
- Kanker Ovarium27 studi
- Gagal Jantung26 studi
- Kanker Pankreas24 studi
Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.